Currently Viewing:
Currently Reading
FDA Approves Besponsa for Relapsed/Refractory Acute Lymphoblastic Leukemia
August 21, 2017 – Alison Rodriguez
Expanded Approval, New Dosage Form for Olaparib in Recurrent Ovarian Cancer
August 18, 2017 – Surabhi Dangi-Garimella, PhD
Understanding Patient Preferences Can Promote Adherence in MS Patients, Study Says
August 18, 2017 – Alison Rodriguez
Phase 1 Trial Indicates Pembrolizumab Safe in Aggressive Small-Cell Lung Cancer
August 18, 2017 – Christina Mattina
Noninvasive ctDNA Test Sensitive to Early-Stage Cancer
August 17, 2017 – Surabhi Dangi-Garimella, PhD
Small Study Confirms Feasibility of a Personalized Neoantigen Vaccine for Melanoma
August 16, 2017 – Surabhi Dangi-Garimella, PhD
Persistent Neuropathy After Chemotherapy Leads to Falls, Disability in Women
August 16, 2017 – Christina Mattina
Cancer Drug Price Increases Cost Medicaid Millions in Extra Spending, Analysis Shows
August 15, 2017 – Christina Mattina
Short-Term CV Risk in Patients With Newly Diagnosed Cancer
August 15, 2017 – Surabhi Dangi-Garimella, PhD

FDA Approves Besponsa for Relapsed/Refractory Acute Lymphoblastic Leukemia

Alison Rodriguez
The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a cancer that occurs when the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.

ALL is a rapidly progressing type of cancer: the National Cancer Institute estimates that approximately 5970 people in the United states will be diagnosed with ALL in 2017, while 1440 will die as a result of the disease. Besponsa is intended to lower these odds by targeting and binding to B-cell ALL cancer cells that have the CD22 antigen and therefore restricting cancerous cells from growing.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement announcing the approval.  

Besponsa was studied in a randomized trial of 326 patients who had relapsed or refractory B-cell ALL and had received 1 or 2 treatments before the study.  The researchers then randomly selected patients to receive Besponsa for treatment or an alternative chemotherapy in order to measure the percentage of patients who demonstrated no evidence of disease and to calculate which patients had a full recovery of blood counts after treatment.

Of the total patients in the trial, 35.8% of those treated with Besponsa reached complete remission for a median 8 months, while of the patients who received chemotherapy, only 17.4% reached complete remission for a median of 4.9 months.

Despite Besponsa’s established efficacy, the treatment causes certain common side effects, including low levels of platelets, low levels of certain white blood cells, infection, anemia, fatigue, and fever.

“These patients have few treatments available and today’s approval provides a new, targeted treatment option,” Pazdur concluded.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up